

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 August 2003 (14.08.2003)

PCT

(10) International Publication Number  
**WO 03/066885 A2**

(51) International Patent Classification<sup>7</sup>: C12Q 1/00

Reinach (CH). **KINZEL, Bernd** [DE/DE]; Friedrich Hecker Str. 34, 79539 Lörrach (DE).

(21) International Application Number: PCT/EP03/01228

(74) Agent: **GROS, Florent**; Novartis AG, Corporate Intellectual Property, Patent and Trademark Department, CH-4002 Basel (CH).

(22) International Filing Date: 7 February 2003 (07.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/355,311 8 February 2002 (08.02.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except AT, US*): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR).

(71) Applicant (*for AT only*): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

**Published:**

— *without international search report and to be republished upon receipt of that report*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ASSELBERGS, Fredericus, Alphonsus, Maria** [NL/CH]; Rainallee 88/3, CH-4125 Riehen (CH). **ATADJA, Peter, Wisdom** [CA/US]; 18 Eastbrook Road, Parsippany, NJ 07054 (US). **HALL, Jonathan** [GB/CH]; Egertenstrasse 9, CH-4153

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 03/066885 A2**

(54) Title: METHOD FOR SCREENING FOR COMPOUNDS HAVING HDAC INHIBITORY ACTIVITY

(57) Abstract: The invention relates to the use of Fra -1 levels as a marker for HDAC inhibition. Also disclosed are in vivo and in vitro methods for screening a compound for HDAC inhibitory activity, as well as methods for monitoring the therapeutic efficacy of an HDAC inhibitor in a subject in vivo and for determining resistance to an HDAC inhibitor in vitro or in vivo.

## **METHOD FOR SCREENING FOR COMPOUNDS HAVING HDAC INHIBITORY ACTIVITY**

### **BACKGROUND OF THE INVENTION**

Histone deacetylases (HDACs) are enzymes that are important regulators of chromatin structure and transcription that modulate the cell cycle, hormone signalling and development. Numerous anti-proliferative effects have been reported for agents that inhibit histone deacetylation, for example, inhibitors of histone deacetylase such as phenylbutyrate and trichostatin A have shown promise in the treatment of promyelocytic leukemia. In addition, butyrate decreases the expression of pro-inflammatory cytokines TNF- $\alpha$ , TNF- $\beta$ , IL-6, and IL1- $\beta$  most likely through inhibition of NF $\kappa$ B activation and inhibition of histone deacetylases. Also, trapoxin A (Tpx A), a microbially derived cyclotetrapeptide (Itazaki et al. J. Antibiot. 43(12):1524-1532 (1990)) has been shown to bind to and potently inhibit histone deacetylase 1 (HDAC1) (Tauton et al. Science 272:408-411 (1996)).

We have now surprisingly discovered that mRNA for Fra-1, a member of the Fos family of proteins implicated in the regulation of cell growth, is down regulated in cells exposed to Tpx A and other HDAC inhibitors. Thus, message levels of Fra-1 can be used as a marker for HDAC activity. The invention provides methods for screening for HDAC inhibition and HDAC inhibitors in vitro and in vivo by detecting Fra-1 levels. The invention also relates to a method for monitoring the therapeutic efficacy of an HDAC inhibitor in a subject in vivo as well as in vivo and in vitro methods to determine resistance to an HDAC inhibitor.

- 2 -

## SUMMARY OF THE INVENTION

In one aspect, the invention pertains to a method for screening for HDAC inhibition in cells in vitro comprising a). detecting Fra-1 levels in said cells and in control cells and b). comparing Fra-1 levels in said cells and in said control cells wherein HDAC inhibition is associated with Fra-1 level down regulation and wherein similar or up regulated levels of Fra-1 compared to control levels indicates that HDACs are not inhibited in said cells in vitro.

10 In another aspect, the invention pertains to a method for screening for HDAC inhibition in a subject in vivo comprising a). detecting Fra-1 levels in said subject in vivo and in a control subject; and b). comparing Fra-1 levels in said subject in vivo and in said control subject wherein HDAC inhibition is associated with Fra-1 level down regulation and wherein similar or up regulated levels of Fra-1 compared to control levels indicates that HDACs are not inhibited in said subject in vivo.

In another aspect the invention pertains to a method for screening a compound for HDAC inhibitory activity in vitro, comprising a). administering a compound to cells in vitro; b). assaying for Fra -1 levels in said cells and in control cells to which no compound has been administered; and c) comparing levels of Fra -1 in said cells and in said control cells wherein HDAC inhibition is associated with Fra-1 level down regulation and wherein similar or up regulated levels of Fra-1 in said cells compared to Fra-1 levels in the control cells indicate that said compound does not have HDAC inhibitory activity.

In another aspect the invention pertains to a method for screening a compound for HDAC inhibitory activity in a subject in vivo, comprising a). assaying for Fra -1 levels in said subject; b). administering a compound to said subject; c). reassaying for Fra -1 levels in said subject after

- 3 -

administration of the compound; and d) comparing Fra -1 levels in said subject before and after administration of the compound wherein HDAC inhibition is associated with Fra-1 level down regulation and wherein similar or up regulated levels of Fra-1 in said subject after administration of the compound compared to levels before compound administration indicate that said compound does not have HDAC inhibitory activity.

In yet another aspect, the invention pertains to a method for monitoring the therapeutic efficacy of a known HDAC inhibitor in a subject comprising a). detecting Fra-1 levels in said subject before and after treatment with said HDAC inhibitor; and b). comparing Fra-1 levels in said subject wherein HDAC inhibition is associated with Fra-1 level down regulation and wherein down regulation of Fra-1 levels in said subject after treatment compared to levels before treatment indicate that the HDAC inhibitor is therapeutically effective.

In still another aspect, the invention relates to a method to determine resistance of a cell to a known HDAC inhibitor comprising a). administering said HDAC inhibitor to cells in vitro; b). screening for Fra-1 levels in said cells and in control cells to which no HDAC inhibitor has been administered, and c). comparing levels of Fra -1 in said cells and in said control cells wherein HDAC inhibition is associated with Fra-1 level down regulation and wherein a lack of Fra-1 level down regulation in said cells compared to Fra-1 levels in the control cells indicates resistance of said cells to the HDAC inhibitor.

In another aspect, the invention relates to a method to determine resistance of a subject to a known HDAC inhibitor comprising a). detecting Fra-1 levels in said subject before and after treatment with said HDAC inhibitor; and b). comparing Fra-1 levels in said subject wherein HDAC inhibition is associated with Fra-1 level down regulation and wherein a lack of

- 4 -

Fra-1 level down regulation in said subject after treatment compared to Fra-1 levels before treatment indicates resistance of said subject to the HDAC inhibitor.

5           In a related aspect the invention relates to a method of diagnosing a proliferative disease susceptible to treatment with HDAC inhibitory agents, which comprises measuring in cells of the subject which exhibits the proliferative disease a decreased level of Fra-1 mRNA or Fra-1 protein. The method preferably takes place ex vivo.

10

In another related aspect Fra-1 is used as a biomarker for HDAC inhibitory activity.

15           In related embodiments of the methods discussed above, Fra-1 protein levels and/or mRNA levels, may be assayed.

#### DETAILED DESCRIPTION OF THE INVENTION

20           It has been found that the message level of Fra-1 is down regulated in mammalian cells exposed to HDAC inhibitors. Because Fra-1 message is consistently down regulated regardless of class of HDAC inhibitor tested, these data indicate that lowered message levels of this protein can be used as a marker for HDAC inhibition in a biological system.

25           While Fra-1 down regulation does not necessarily indicate HDAC inhibition in a cell culture or in vivo subject, data disclosed herein indicate that HDAC inhibition is associated with Fra-1 message level down regulation. Based on this observation, it is clear that a normal or up regulated level of Fra-1 in a culture or subject compared to control levels definitively indicates  
30           that HDACs are not inhibited in said culture or subject. Such information can be used to biochemically characterize a particular cell type, including, for

- 5 -

example, primary cultures of diseased cells from a subject or established cell lines as well as provide information regarding a disease state or other pathological condition in vivo and may thus provide useful information regarding appropriate clinical treatment options.

5

In one aspect, therefore, the present invention pertains to a method for screening for HDAC inhibition in vitro or in vivo comprising detecting Fra-1 levels in vitro or in vivo and comparing with Fra-1 levels in appropriate controls. In this case, "appropriate controls" refers to cultures or in vivo  
10 subjects (as the case may be) which may be used to provide Fra-1 levels for comparison and will be familiar to one of skill in the art. Similarly, conventional scientific techniques and procedures familiar to one of skill in the art may be employed to practice this screening method.

15

HDAC inhibitors may be suitable for use as therapeutic agents in mammals, including animals in veterinary medicine or humans, in need of treatment of diseases in which HDAC inhibition is desirable. Such conditions include, but are not limited to, atherosclerosis, inflammatory bowel disease,  
20 host inflammatory or immune response, psoriasis and conditions associated with abnormal cell proliferation, such as cancer. In a preferred embodiment the condition is a proliferative disease such as cancer. Thus, given the clinical importance of HDAC inhibitors, a method to facilitate the detection of such useful therapeutic compounds from a chemical compound library of  
25 thousands is of significant value. Based on the surprising discovery that HDAC inhibition is associated with Fra-1 message down regulation, it is contemplated herein that Fra-1 message levels can be used in a method to facilitate the identification of novel HDAC inhibitors by permitting the identification of compounds that are clearly not HDAC inhibitors. Compounds  
30 which are not HDAC inhibitors can be identified as those compounds which do not cause a down regulation in Fra-1 levels (e.g. mRNA levels and/or

- 6 -

protein levels) compared to appropriate controls. These compounds may then be eliminated from the "list" of possible HDAC inhibitors and need not be tested further. Attention may then be focused on those compounds that actually cause down regulation of Fra-1 levels which may then be further  
5 assayed using conventional methods to better characterize effects on HDAC activity.

Thus, in another aspect, the invention pertains to a method for screening a compound for HDAC inhibitory activity in vivo comprising  
10 assaying for Fra -1 levels in a subject, administering a compound to said subject; reassaying for Fra -1 levels in said subject after administration of the compound; and comparing Fra -1 levels in said subject before and after administration of the compound wherein HDAC inhibition is associated with Fra-1 level down regulation and wherein similar or up regulated levels of Fra-  
15 1 in said subject after administration of the compound compared to levels before compound administration indicates that said compound does not have HDAC inhibitory activity.

The in vivo screening assay may be performed using conventional  
20 methods. For example, conventional methods may be used to assay levels of Fra- 1 mRNA in vivo in a biological sample taken from a subject before and after compound administration. Similarly, test subjects may include, but are not limited to, conventional experimental animal models such as mouse xenograft, orthotopic or metastatic tumor models as well as human patients in  
25 controlled, clinical studies familiar to one of skill in the art.

The screening method may also be performed in vitro. Thus, in another aspect the invention pertains to a method for screening a compound for HDAC inhibitory activity in vitro, comprising administering a compound to  
30 cells in vitro, assaying for Fra -1 levels in said cells and in control cells to which no compound has been administered, and comparing levels of Fra -1

- 7 -

in said cells and in said control cells wherein HDAC inhibition is associated with Fra-1 level down regulation and wherein similar or up regulated levels of Fra-1 in said cells compared to Fra-1 levels in control cells indicate that said compound does not have HDAC inhibitory activity.

5

Like the in vivo method, the in vitro screening method may be performed using techniques familiar to one of skill in the art. For example, a compound may be screened in vitro using primary cells isolated from human or other mammalian subjects or using a variety of cell lines such as H1299, A549, HCT116 or any other cells in which Fra1 mRNA may be detectably expressed. As used herein, "cells in which Fra-1 levels may be detectably expressed" refers to cells which express levels of Fra-1 mRNA and/or Fra-1 protein such that said levels are sufficient for detection according to conventional methods. Such cell lines are available commercially, for example, from the ATCC (Manassas, Virginia) and may be discerned by one of skill in the art without undue experimentation. Likewise, a test compound may be administered to cells in vitro and down regulation of Fra-1 assayed according to conventional methods.

20

The present invention also provides a method for monitoring the therapeutic efficacy of a known HDAC inhibitor in a subject comprising detecting Fra-1 levels in a said subject before and after treatment with said HDAC inhibitor; and comparing Fra-1 levels in said subject wherein HDAC inhibitor is associated with Fra-1 level down regulation and wherein down regulation of Fra-1 levels in said subject after treatment compared to levels before treatment indicate that the HDAC inhibitor is therapeutically effective. For example, circulating tumor epithelial cells, may be purified from the blood of patients undergoing HDAC inhibitor treatment (i.e. biological samples obtained before and after treatment), RNA purified from these cells and Fra-1 levels determined in the samples by RT-PCR according to conventional

30



- 8 -

methods. A lack of Fra-1 down regulation in a patient to whom an HDAC inhibitor has been administered would be indicative of a lack of HDAC inhibition in said patient and would therefore indicate a corresponding lack in therapeutic efficacy.

5

Thus, Fra-1 levels may be used as a clinical marker to optimize the dosage and the regimen of an HDAC inhibitor by monitoring Fra-1 levels in the subject's biological sample and dosing to achieve a desirable level of down regulation. Accordingly, the method of the present invention can be used to monitor the therapeutic efficacy of a compound and/or to find a therapeutically effective amount or regimen for the selected compound, thereby individually selecting and optimizing a therapy for a patient. Factors for consideration in this context include the particular condition being treated, the particular mammal being treated, the clinical condition of the individual patient, the site of delivery of the active compound, the particular type of the active compound, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The therapeutically effective amount of an HDAC inhibitor to be administered will be governed by such considerations, and is the minimum amount necessary to prevent, ameliorate, or treat the disease. Such amount is preferably below the amount that is toxic to the host or renders the host significantly more susceptible to infections.

Levels of expression of Fra- 1 can be assayed from a biological sample by any known method, including conventional techniques of RNA quantitation such as Northern blot analysis, quantitative PCR or DNA microarrays (e.g. as commercialised by Affymetrix, Santa Clara, CA). As used herein, "biological sample" may comprise blood, urine or other biological material which may be used to assay Fra-1 mRNA or protein levels.

30

As data indicate that HDAC inhibition is associated with Fra-1 down regulation, one may analyze Fra-1 levels in the presence of an HDAC inhibitor as a way to detect the effect of an HDAC inhibitor in vitro or in vivo.

5 In a another aspect the invention relates to a method of diagnosing a proliferative disease susceptible to treatment with HDAC inhibitory agents, which comprises measuring in cells of the subject which exhibits the proliferative disease a decreased level of Fra-1 mRNA or Fra-1 protein. Said measuring preferably takes place ex vivo, i.e. outside of the body, for instance  
10 using tissue or blood which had previously been isolated from said subject.

Specifically, in another aspect, the invention relates to a method to determine resistance of a cell to a known HDAC inhibitor comprising administering said HDAC inhibitor to cells in vitro, screening for Fra-1 levels  
15 in said cells and in control cells to which no HDAC inhibitor has been administered, and comparing levels of Fra -1 in said cells and in said control cells wherein HDAC inhibition is associated with Fra-1 level down regulation and wherein a lack of Fra-1 level down regulation in said cells compared to Fra-1 levels in the control cells indicates resistance of said cells  
20 to the HDAC inhibitor. Cells that may be analyzed according to this method include, but are not limited to, tumor cell lines as well as primary cultures of neoplastic or other cells obtained from a patient's biological sample.

Similarly, in a related aspect, the invention relates to a method to  
25 determine resistance of a subject to a known HDAC inhibitor comprising a). detecting Fra-1 levels in said subject before and after treatment with said HDAC inhibitor; and b). comparing Fra-1 levels in said subject wherein HDAC inhibition is associated with Fra-1 level down regulation and wherein a lack of Fra-1 level down regulation in said subject after treatment compared  
30 to Fra-1 levels before treatment indicates resistance of said subject to the HDAC inhibitor. As is the case with all aspects of the invention disclosed

- 10 -

herein, administration of HDAC inhibitors and analysis of Fra-1 levels in vitro and in vivo in order to determine resistance to an HDAC inhibitor may be performed according to a variety of conventional methods familiar to one of skill in the art.

5

In addition to measuring mRNA levels of Fra -1 as discussed in the various aspects above, it is also contemplated herein that one may also analyze Fra-1 protein levels in such cases where HDAC inhibition is not only associated with down regulation of Fra-1 mRNA levels but also with a  
10 corresponding down regulation in Fra-1 protein levels in vivo or in vitro. Levels of Fra -1 protein may be detected using conventional techniques, for example, immunoassays or electrophoresis assays. For example, immunoassays can be used to detect or monitor levels of Fra-1 in a biological sample using Fra-1 specific polyclonal or monoclonal antibodies in any  
15 standard immunoassay format to measure Fra-1. ELISA (enzyme linked immunosorbent assay) type assays as well as conventional Western blotting assays using monoclonal antibodies are also exemplary assays that can be utilized to make direct determination of levels of the marker protein. Antibodies specific to Fra-1 are available commercially (for example, rabbit  
20 anti-human Fra-1 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or can be produced in accordance with known methods. For example, monoclonal antibodies against Fra-1 may be produced according to conventional methods, for example, as described in Harlow, E. and Lane, eds., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory  
25 Press, Cold Spring Harbor.

In practicing the present invention, many other conventional techniques in molecular biology may be used. These techniques are well known and are explained in, for example, Current Protocols in Molecular Biology, Volumes I,  
30 II, and III, 1997 (F. M. Ausubel ed.); Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor

- 11 -

Laboratory Press, Cold Spring Harbor, N.Y.; DNA Cloning: A Practical Approach, Volumes I and II, 1985 (D. N. Glover ed.); Oligonucleotide Synthesis, 1984 (M. L. Gait ed.); Nucleic Acid Hybridization, 1985, (Hames and Higgins); Transcription and Translation, 1984 (Hames and Higgins eds.);  
5 Animal Cell Culture, 1986 (R. I. Freshney ed.); Immobilized Cells and Enzymes, 1986 (IRL Press); Perbal, 1984, A Practical Guide to Molecular Cloning; the series, Methods in Enzymology (Academic Press, Inc.); Gene Transfer Vectors for Mammalian Cells, 1987 (J. H. Miller and M. P. Calos eds., Cold Spring Harbor Laboratory); and Methods in Enzymology Vol. 154  
10 and Vol. 155 (Wu and Grossman, and Wu, eds., respectively).

The following examples further illustrate the present invention and are not intended to limit the invention.


## EXAMPLES

## EXAMPLE 1



Differential expression of Fra-1 in H1299 and A549  
cells after TPX treatment

## Materials and Methods-

Various compounds that inhibit or modulate the enzymatic activities of HDACs (HDAC inhibitors) include Tpx A, phenylbutyrate, trichostatin A as well as the benzamide known as MS-27-275. (Jung (2001) Current Medicinal Chemistry 8, 1505-1511). Data disclosed herein are the results of experiments using Tpx A (prepared according to the method disclosed in Itazaki et al., J. Antibiotics (Tokyo) 43(12):1524-32 (1990)) and also using several hydroxamate compounds which are histone deacetylase inhibitors, *N*-Hydroxy-3-[4-[[[2-(1*H*-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2*E*-2-propenamide, referred to herein as "Compound A" and *N*-Hydroxy-3-[4-[[[(2-hydroxyethyl)[2-(1*H*-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2*E*-2-propenamide, referred to herein as "Compound B". These compounds and their synthesis are discussed in detail in WO02/22577.



- 13 -

**Compound A****5 Compound B**

Compound A may be prepared according to the following synthesis:  
4-formylcinnamic acid methylester is produced by adding 4-formylcinnamic acid (25 g, 0.143 mol) in MeOH and HCl (6.7 g, 0.18 mol). The resulting  
10 suspension is heated to reflux for 3 hours, cooled and evaporated to dryness. The resulting yellow solid is dissolved in EtOAc, the solution washed with saturated NaHCO<sub>3</sub>, dried (MgSO<sub>4</sub>) and evaporated to give a pale yellow solid which is used without further purification (25.0 g, 92%). To a solution of  
tryptamine (16.3 g, 100 mmol) and 4-formylcinnamic acid methylester (19 g,  
15 100 mmol) in dichloroethane, NaBH(OAc)<sub>3</sub> (21 g, 100 mmol) is added. After 4 hours the mixture is diluted with 10% K<sub>2</sub>CO<sub>3</sub> solution, the organic phase separated and the aqueous solution extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic extracts are dried (Na<sub>2</sub>SO<sub>4</sub>), evaporated and the residue purified by flash chromatography to produce 3-(4-[[2-(1*H*-indol-3-yl)-ethylamino]-methyl]-phenyl)-(2*E*)-2-propenoic acid methyl ester (29 g). A solution of KOH (12.9 g  
20 87%, 0.2 mol) in MeOH (100 mL) is added to a solution of HONH<sub>2</sub>•HCl (13.9

- 14 -

g, 0.2 mol) in MeOH (200 mL) and a precipitate results. After 15 minutes the mixture is filtered, the filter cake washed with MeOH and the filtrate evaporated under vacuum to approximately 75 mL. The mixture is filtered and the volume adjusted to 100 mL with MeOH. The resulting solution 2M  
5 HONH<sub>2</sub> is stored under N<sub>2</sub> at -20° C for up to 2 weeks. Then 3-(4-([2-(1*H*-indol-3-yl)-ethylamino]-methyl)-phenyl)-(2*E*)-2-propenoic acid methyl ester (2.20 g, 6.50 mmol) is added to 2 M HONH<sub>2</sub> in MeOH (30 mL, 60 mmol) followed by a solution of KOH (420 mg, 6.5 mmol) in MeOH (5 mL). After 2 hours dry ice is added to the reaction and the mixture is evaporated to  
10 dryness. The residue is dissolved in hot MeOH (20 mL), cooled and stored at -20 °C overnight. The resulting suspension is filtered, the solids washed with ice cold MeOH and dried under vacuum, producing *N*-Hydroxy-3-[4-([2-(1*H*-indol-3-yl)-ethyl]-amino)methyl]phenyl]-2*E*-2-propenamide (m/z 336 [MH<sup>+</sup>]).

15 Compound B may be prepared according to the following synthesis:  
A solution of 3-(4-([2-(1*H*-indol-3-yl)-ethylamino]-methyl)-phenyl)-(2*E*)-2-propenoic acid methyl ester (12.6 g, 37.7 mmol), (2-bromoethoxy)-tert-butyltrimethylsilane (12.8 g, 53.6 mmol), (*i*-Pr)<sub>2</sub>NEt, (7.42 g, 57.4 mmol) in DMSO (100 mL) is heated to 50° C. After 8 hours the mixture is partitioned  
20 with CH<sub>2</sub>Cl<sub>2</sub>/H<sub>2</sub>O. The organic layer is dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated. The residue is chromatographed on silica gel to produce 3-[4-([2-(*tert*-butyldimethylsilyloxy)-ethyl]-[2-(1*H*-indol-3-yl)-ethyl]-amino)-methyl]-phenyl)-(2*E*)-2-propenoic acid methyl ester (13.1 g). Following the procedure described above for the preparation of Compound A, 3-[4-([2-(*tert*-  
25 butyldimethylsilyloxy)-ethyl]-[2-(1*H*-indol-3-yl)-ethyl]-amino)-methyl]-phenyl)-(2*E*)-2-propenoic acid methyl ester (5.4 g, 11 mmol) is converted to *N*-hydroxy-3-[4-([2-(*tert*-butyldimethylsilyloxy)-ethyl]-[2-(1*H*-indol-3-yl)-ethyl]-amino)-methyl]-phenyl)-(2*E*)-2-propenamide (5.1 g,) and used without further purification. The hydroxamic acid (5.0 g, 13.3 mmol) is then dissolved in 95%  
30 TFA/H<sub>2</sub>O (59 mL) and heated to 40 - 50 °C for 4 hours. The mixture is evaporated and the residue purified by reverse phase HPLC to produce *N*-

- 15 -

Hydroxy-3-[4-[[[(2-hydroxyethyl)[2-(1*H*-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2*E*-2-propenamide as the trifluoroacetate salt (2.19 g).

Human H1299 non-small cell lung carcinoma cells (ATCC, Manassas,  
5 VA) (ATCC # CRL-5803) are cultured in RPMI 1640 medium (Life  
Technologies, Gaithersburg, MD) containing 10% fetal bovine serum (FBS,  
Life Technologies) plus 50 µg/ml Gentamycin (Life Technologies) in a  
humidified incubator with a 5% CO<sub>2</sub> atmosphere at 37°C. Prior to Tpx A  
treatment, H1299 cells are plated at a density of 2x10<sup>5</sup> cells/well in 6 well  
10 plates (Costar, Coming, NY) and grown up for 24 h. Tpx A (1mM stock  
solution in DMSO) is added to the cells at concentrations from 1 to 1000 nM  
and cells are incubated for either 24 or 48 hours at 37°C.

Human A549 non-small lung carcinoma cells (ATCC CCL-185,  
15 Manassas, VA) are cultured in DMEM medium (Life Technologies,  
Gaithersburg, MD) containing 4500 mg/l glucose, 10% fetal bovine serum  
(FBS, Life Technologies) plus 50 µg/ml Gentamycin (Life Technologies) in a  
humidified incubator with a 5% CO<sub>2</sub> atmosphere at 37°C. Prior to Tpx A  
treatment, A549 cells are plated at a density of 2x10<sup>5</sup> cells/well in 6 well plates  
20 (Costar, Coming, NY) and grown up for 24 h. Tpx A (1mM stock solution in  
DMSO) is added to the cells at concentrations from 1 to 1000 nM and cells  
are incubated for either 24 or 48 hours h at 37°C.

Total RNA from Tpx A treated as well as untreated H1299 and A549  
25 cells is prepared using the RNeasy Mini kit (Qiagen, Hilden, Germany)  
according to the manufacturer's instructions. The RNA is recovered in 50 µl  
DEPC- treated H<sub>2</sub>O (RNase free) and the RNA concentration is determined by  
measuring the OD<sub>260</sub> in a SpectraMax photometer (Molecular Devices,  
Sunnyvale, CA).

30



- 16 -

Sequences for primers (BIG, Freiburg, Germany) and TaqMan probes for Q-PCR containing 5' FAM fluorescent reporter and 3' TAMRA quencher dyes (Eurogentec, Seraing, Belgium) are selected using the Primer Express Software (Applied Biosystems, Foster City, CA) at default settings; Primer T<sub>m</sub> Requirements: Min T<sub>m</sub>: 58°C, Max T<sub>m</sub>: 60°C, Optimal T<sub>m</sub>: 59°C, Maximal T<sub>m</sub> difference: 2°C. Primer GC Content Requirements: Min %GC 30, Max %GC 80, 3' clamp of 0 residues. Primer Length Requirements: Min length: 9, Max length: 40, optimal length: 20. Amplicon Requirements: Min T<sub>m</sub>: 0°C, Max T<sub>m</sub>: 85°C, Min length: 50, Max length: 150. TaqMan Probe Criteria: TaqMan probe T<sub>m</sub> must be 10°C greater than PCR primer T<sub>m</sub>.

Primers used are:

Forward: 5'-CAACCCTCCTCGCTTTGTGA-3'; Seq. ID. No 1

Reverse: 5'-GACATTGGCTAGGGTGGCAT-3'; Seq. ID. No 2

Taqman: 5'-CGCCTGAGCCCTACTCCCTGCA-3' . Seq. ID. No 3

Q-PCR is performed using the TaqMan PCR Core reagent kit (Applied Biosystems Foster City, CA) in a ABI Prism 7700 sequence detector (Applied Biosystems) according to the manufacturer's instructions. 50 ng total RNA in 12 µl DEPC-H<sub>2</sub>O are prepared in MicroAmp optical 96 well reaction plates (Applied Biosystems) together with 13 µl TaqMan PCR reagent mix as provided in Table 1.

- 17 -

Table 1

Reagent	Volume/sample	Final concentration
10 x TaqMan buffer	2.5 $\mu$ l	1 x
25 mM MgCl <sub>2</sub>	5.5 $\mu$ l	5.5 mM
10 mM dATP	0.75 $\mu$ l	300 $\mu$ M
10 mM dCTP	0.75 $\mu$ l	300 $\mu$ M
10 mM dGTP	0.75 $\mu$ l	300 $\mu$ M
20 mM dUTP	0.75 $\mu$ l	600 $\mu$ M
RNase inhibitor (20 u/ $\mu$ l)	0.25 $\mu$ l	0.2 u/ $\mu$ l
AmpliTaq GOLD (5 u/ml)	0.125 $\mu$ l	0.025 u/ $\mu$ l
MuLV rev.transcript.(50 u/ml)	0.125 $\mu$ l	0.25 u/ $\mu$ l
10 $\mu$ M forward primer	0.5 $\mu$ l	200 nM
10 $\mu$ M reverse primer	0.5 $\mu$ l	200 nM
5 $\mu$ M TaqMan probe	0.5 $\mu$ l	100 nM
50 ng RNA in DEPC-H <sub>2</sub> O	12 $\mu$ l	2 ng/ $\mu$ l

Settings for reverse transcription of the target RNA and detection by Q-  
5 PCR are 50°C for 2 min., 95°C for 10 min. followed by 50 cycles of 95°C for

- 18 -

15 sec and 60°C for 1 min. Relative measurement of the amplified product is performed using the comparative C<sub>T</sub> method as described in the manufacturer's manual (Applied Biosystems, ABI Prism 7700 sequence detection system, User Bulletin #2).

- 5 Data using real time Q-PCR indicate that Fra-1 is highly repressed by treatment with the HDAC inhibitor as seen in both H1299 cells (Tables 2, 4) and A549 cells (Tables 3, 5) over a wide dose range 10-1000nM. These data also confirm results obtained using conventional microarray technology which indicate that the expression of Fra-1 mRNA is highly repressed (>200 fold) in  
10 the same cell lines in the presence of TPX A (data not shown).

**Table 2**

15 **Relative levels of Fra-1 mRNA in H1299 cells  
after 24 hours Tpx A treatment measured by Q-PCR**

Concentration of TPX A (nM)	% Fra1 mRNA remaining
0	100
1	98
10	2
50	1
100	1
250	1
500	1
1000	1
DMSO 10	not determined
DMSO 1000	not determined

- 19 -

Table 3

5      **Relative levels of Fra-1 mRNA in A549 cells  
after 24 hours Tpx A treatment measured by Q-PCR.**

<b>Concentration of TPX A (nM)</b>	<b>% Fra1 mRNA remaining</b>
0	103
1	95
10	64
50	26
100	16
250	6
500	4
1000	3
DMSO 10	106
DMSO 1000	88

Table 4

10      **Relative levels of Fra-1 mRNA in H1299 cells  
after 48 hours Tpx A treatment measured by Q-PCR**

<b>Concentration of TPX A (nM)</b>	<b>% Fra1 mRNA remaining</b>
0	101
1	94
10	7
50	1
100	1
250	1
500	1
1000	1
DMSO 10	82
DMSO 1000	78

1

Table 5

5                    **Relative levels of Fra-1 mRNA in A549 cells  
after 48 hours Tpx A treatment measured by Q-PCR.**

<b>Concentration of TPX A (nM)</b>	<b>% Fra1 mRNA remaining</b>
0	104
1	93
10	84
50	38
100	32
250	14
500	7
1000	6
DMSO 10	106
DMSO 1000	77

10                    The IC<sub>50</sub>'s were determined as ranging between 1-10nM and 10-50nM in the  
H1299 cell line and in the A549 cell line, respectively.

## EXAMPLE 2

**Differential expression of Fra-1 in H1299 and HCT116 cells after  
treatment with Tpx A or Compound A.**

15                    H1299 cells and HCT116 cells (ATCC, Manassas, VA) are cultured and  
exposed to Tpx A or Compound A and levels of Fra-1 message assayed. In  
these experiments, H1299 cells are cultured as described in Example 1.  
HCT116 cells are cultured in RPMI 1640 medium containing 10% fetal calf  
20                    serum at 37°C and 5% CO<sub>2</sub>. 100 nM trapoxin, 100nM Compound A or 100 nM  
DMSO are added to the cells at 60% confluence and grown up for either 6 or  
24 hours. Using methodologies as described in Example 1 above, the RNA  
from cultures treated with Tpx A, Compound A or DMSO as a control is

- 21 -

obtained and analysed by Q-PCR for Fra-1 levels; in this case, 8.7 ng total RNA in 12 µl DEPC-H<sub>2</sub>O are prepared in MicroAmp optical 96 well reaction plates (Applied Biosystems) together with 13 µl TaqMan PCR reagent mix as provided in Table 1.

- 5 Data in Tables 6 and 7 indicate that Fra -1 message is down regulated compared to control cultures not only in H1299 and HCT116 cells treated with Tpx A but also in cultures treated with Compound A.

10 **Table 6**  
**Relative levels of Fra-1 mRNA in H1299 cells after treatment with HDAC inhibitors measured by Q-PCR at 2 timepoints.**

Drug added	% Fra1 mRNA remaining
DMSO 6hr	100.96
DMSO 24hr	94.83
TPX A 6hr	5.81
TPX A 24hr	3.11
Compound A 6hr	7.14
Compound A 24hr	2.07

15 **Table 7**  
**Relative levels of Fra-1 mRNA in HCT116 cells after treatment with HDAC inhibitors measured by Q-PCR at 2 timepoints.**

Drug added	% Fra1 mRNA remaining
DMSO 6hr	100.48
DMSO 24hr	56.17
TPX A 6hr	14.25
TPX A 24hr	13.68
Compound A 6hr	32.59
Compound A 24hr	15.89

Additional analysis of H1299 and HCT116 cells treated with other HDAC inhibitors (data not shown) also indicates reduced levels of Fra-1 expression in the presence of these inhibitors, thus enforcing the link between Fra-1 levels and HDAC activity. The fact that different HDAC inhibitors can  
5 cause inhibition of Fra1 expression in different cell lines is strong evidence that the down regulation of Fra-1 message level is a result of HDAC inhibition and not due to unrelated side effects associated with treatment of particular cells with a particular compound.

10

### EXAMPLE 3

#### Differential expression of Fra-1 in A549 cells after treatment with Compound B

Human A549 non-small cell lung carcinoma cells (ATCC, Manassas,  
15 VA) (ATCC # CCL-185) are cultured in DMEM medium (Life Technologies, Gaithersburg, MD) containing 10% fetal bovine serum (FBS, Life Technologies) plus 50 µg/ml Gentamycin (Life Technologies) in a humidified incubator with a 5% CO<sub>2</sub> atmosphere at 37°C. Prior to Compound B treatment, A549 cells are plated at a density of 5x10<sup>4</sup> cells/well in 24 well  
20 plates (Costar, Coming, NY) and grown up for 24 h. Compound B (10 mM stock solution in DMSO) is diluted to a final concentration of 100 nM in tissue culture medium and added to the cells. As control an equivalent amount of DMSO is added to control cultures without Compound B. The cells are incubated at 37°C for either 16, 24 or 48 hrs. All cell cultures are set up in  
25 duplicate. Total RNA from the compound - treated as well as untreated A549 cells is prepared using the RNeasy Mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The RNA is recovered in 50 µl DEPC- treated H<sub>2</sub>O (RNase free) and the RNA concentration is determined by measuring the OD<sub>260</sub> in a SpectraMax photometer (Molecular Devices,  
30 Sunnyvale, CA). The amount of RNA is adjusted to 5 ng/microliter. For each

- 23 -

RNA sample duplicate 25 microliter Q-PCR reactions are setup as listed in Table 8.

**Table 8**

<b>Reagent</b>	<b>Volume/sample</b>	<b>Final concentration</b>
10 x TaqMan buffer	2.5 µl	1 x
25 mM MgCl <sub>2</sub>	5.5 µl	5.5 mM
10 mM dATP	0.75 µl	300 µM
10 mM dCTP	0.75 µl	300 µM
10 mM dGTP	0.75 µl	300 µM
20 mM dUTP	0.75 µl	600 µM
RNase inhibitor (20 u/µl)	0.25 µl	0.2 u/µl
AmpliTaq GOLD (5 u/ml)	0.125 µl	0.025 u/µl
MuLV rev.transcript.(50 u/ml)	0.125 µl	0.25 u/µl
10 µM forward primer	0.5 µl	200 nM
10 µM reverse primer	0.5 µl	200 nM
5 µM TaqMan probe	0.5 µl	100 nM
50 ng RNA in DEPC-H <sub>2</sub> O	10 µl	2 ng/µl
DEPC-H <sub>2</sub> O	2 µl	



- 24 -

DNA sequence of the Fra-1 primers and probes are as described above. Settings for reverse transcription of the target RNA and detection by Q-PCR are 50°C for 2 min., 95°C for 10 min. followed by 50 cycles of 95°C for 15 sec and 60°C for 1 min. Relative measurement of the amplified product is performed using the comparative  $C_T$  method as described in the manufacturer's manual (Applied Biosystems, ABI Prism 7700 sequence detection system, User Bulletin #2). Results are expressed as a percentage of the amount of Fra-1 mRNA recovered from untreated cells. Data indicate that Fra-1 is highly repressed over a prolonged period of time in A549 cells exposed to Compound B compared to controls (Table 9).

**Table 9**  
**Relative levels of Fra-1 mRNA in A549 cells after treatment with HDAC inhibitor Compound B measured by Q-PCR at 3 timepoints.**

Drug added	% Fra1 mRNA remaining	STDEV (n=4)
DMSO 16hr	100.0	14.6
DMSO 24hr	100.0	0.9
DMSO 48hr	100.0	0.7
Compound B 16hr	15.0	1.5
Compound B 24hr	14.1	0.6
Compound B 48hr	52.8	4.7

#### **Example 4**

##### **Histone Deactylase Activity in the presence of Trapoxin A, Compound A and Compound B**

Using conventional methodologies, the actual enzyme activity of Histone H4 was examined in the presence of Trapoxin A, Compound A or Compound B. Briefly, 30,000 cpm of a tritium labeled acetylated Histone H4

- 25 -

peptide is incubated with histone deacetylase activity purified from H1299 cells by ion exchange chromatography in HDAC assay buffer (10 mM Tris-Cl, pH 8.0, 10 mM NaCl, 10% glycerol) in the presence or absence of drug. The mixture is allowed to sit for 2 hours at 37°C and radio-labeled acetyl groups released by histone deacetylase activity extracted into ethyl acetate and counted on a scintillation counter. The IC<sub>50</sub> represents the concentration of drug that inhibits 50% of the histone deacetylase activity obtained in the absence of drug. Data verify that Trapoxin A, Compound A and Compound B possess HDAC inhibitory activity and support the finding that administration of these compounds to cells as disclosed in the Examples contained herein not only results in the down regulation of Fra-1 but that this down regulation is associated with actual HDAC inhibition in these cells (see Table 10).

Table 10

HDAC activity in the presence of Trapoxin, Compound A and Compound B

Compound	IC <sub>50</sub> /μM on histone deacetylase
Trapoxin	2.2 ± 0.96
Compound A	0.063 ± 0.01
Compound B	0.032 ± 0.017

## WHAT IS CLAIMED IS:

1. A method for screening for HDAC inhibition in cells in vitro comprising

- 5 a). detecting Fra-1 levels in said cells and in control cells; and,  
b). comparing Fra-1 levels in said cells and in said control cells

wherein HDAC inhibition is associated with Fra-1 level down regulation and wherein similar or up regulated levels of Fra-1 compared to control levels indicate that HDACs are not inhibited in said cells in vitro.

10

2. The method of claim 1 wherein said Fra-1 levels is the level of Fra-1 mRNA.

15

3. The method of claim 1 wherein said Fra-1 levels is the level of Fra-1 protein.

4. A method for screening for HDAC inhibition in a subject in vivo comprising

20

- a). detecting Fra-1 levels in said subject in vivo and in a control subject; and,  
b). comparing Fra-1 levels in said subject in vivo and in said control subject

25 wherein HDAC inhibition is associated with Fra-1 level down regulation and wherein similar or up regulated levels of Fra-1 compared to control levels indicate that HDACs are not inhibited in said subject in vivo.

- 27 -

5. The method of claim 4 wherein said Fra-1 levels is the level of Fra-1 mRNA.

5 6. The method of claim 4 wherein said Fra-1 levels is the level of Fra-1 protein.

7. A method for screening a compound for HDAC inhibitory activity in vitro, comprising

10 a). administering a compound to cells in vitro;  
b). assaying for Fra -1 levels in said cells and in control cells to which no compound has been administered; and,  
c) comparing levels of Fra -1 in said cells and in said control cells

15 wherein HDAC inhibition is associated with Fra-1 level down regulation and wherein similar or up regulated levels of Fra-1 in said cells compared to Fra-1 levels in control cells indicate that said compound does not have HDAC inhibitory activity.

20 8. The method of claim 7 wherein said Fra-1 levels is the level of Fra-1 mRNA.

9. The method of claim 7 wherein said Fra-1 levels is the level of Fra-1 protein.

25 10. A method for screening a compound for HDAC inhibitory activity in a subject in vivo, comprising

30 a). assaying Fra -1 levels in said subject;  
b). administering a compound to said subject;

- 28 -

c). reassaying Fra -1 levels in said subject after administration of the compound; and,

d) comparing Fra -1 levels in said subject before and after administration of the compound

5

wherein HDAC inhibition is associated with Fra-1 level down regulation and wherein similar or up regulated levels of Fra-1 in said subject after administration of the compound compared to levels before compound administration indicate that said compound does not have HDAC inhibitory activity.

10

11. The method of claim 10 wherein said Fra-1 levels is the level of Fra-1 mRNA.

15

12 . The method of claim 4 wherein said Fra-1 levels is the level of Fra-1 protein.

13. A method for monitoring the therapeutic efficacy of a known HDAC inhibitor in a subject comprising

20

a). detecting Fra-1 levels in said subject before and after treatment with said HDAC inhibitor; and,  
b). comparing Fra-1 levels in said subject

25

wherein HDAC inhibition is associated with Fra-1 level down regulation and wherein down regulation of Fra-1 levels in said subject after treatment compared to levels before treatment indicate that the HDAC inhibitor is therapeutically effective.

14. The method of claim 13 wherein said Fra-1 levels is the level of Fra-1 mRNA.

5 15. The method of claim 13 wherein said Fra-1 levels is the level of Fra-1 protein.

16. A method to determine resistance of a cell to a known HDAC inhibitor comprising

- 10 a). administering said HDAC inhibitor to said cells in vitro; and,  
b). screening for Fra-1 levels in said cells and in control cells to which no HDAC inhibitor has been administered; and,  
c). comparing levels of Fra -1 in said cells and in said control cells

15 wherein HDAC inhibition is associated with Fra-1 level down regulation and wherein a lack of Fra-1 level down regulation in said cells compared to Fra-1 levels in the control cells indicates resistance of said cells to the HDAC inhibitor.

20 17. The method of claim 16 wherein said Fra-1 levels is the level of Fra-1 mRNA.

18. The method of claim 16 wherein said Fra-1 level is the level of Fra-1 protein.

25 19. A method to determine resistance of a subject to a known HDAC inhibitor comprising

- a). detecting Fra-1 levels in said subject before and after treatment with said HDAC inhibitor; and,  
30 b). comparing Fra-1 levels in said subject

- 30 -

wherein HDAC inhibition is associated with Fra-1 level down regulation and wherein a lack of Fra-1 level down regulation in said subject after treatment compared to Fra-1 levels before treatment indicates resistance of said subject to the HDAC inhibitor.

5

20. The method of claim 19 wherein said Fra-1 levels is the level of Fra-1 mRNA.

10

21. The method of claim 19 wherein said Fra-1 level is the level of Fra-1 protein.

15

22. A method of diagnosing a proliferative disease susceptible to treatment with HDAC inhibitory agents, which comprises measuring in cells of the subject which exhibits the proliferative disease a decreased level of Fra-1 mRNA or Fra-1 protein.

20

23. The method of claim 22 wherein the measurement takes place ex vivo.

25

24. Use of Fra-1 as a biomarker for HDAC inhibitory activity.





(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 August 2003 (14.08.2003)

PCT

(10) International Publication Number  
**WO 03/066885 A3**

- (51) International Patent Classification<sup>7</sup>: C12Q 1/44 (74) Agent: GROS, Florent; Novartis AG, Corporate Intellectual Property, Patent and Trademark Department, CH-4002 Basel (CH).
- (21) International Application Number: PCT/EP03/01228
- (22) International Filing Date: 7 February 2003 (07.02.2003) (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/355,311 8 February 2002 (08.02.2002) US (84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR).
- (71) Applicant (*for all designated States except AT, US*): NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- (71) Applicant (*for AT only*): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): ASSELBERGS, Fredericus, Alphonsus, Maria [NL/CH]; Rainallee 88/3, CH-4125 Riehen (CH). ATADJA, Peter, Wisdom [CA/US]; 18 Eastbrook Road, Parsippany, NJ 07054 (US). HALL, Jonathan [GB/CH]; Egertenstrasse 9, CH-4153 Reinach (CH). KINZEL, Bernd [DE/DE]; Friedrich Hecker Str. 34, 79539 Lörrach (DE).
- Published:  
— with international search report  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report:  
11 December 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/066885 A3

(54) Title: METHOD FOR SCREENING FOR COMPOUNDS HAVING HDAC INHIBITORY ACTIVITY

(57) Abstract: The invention relates to the use of Fra -1 levels as a marker for HDAC inhibition. Also disclosed are in vivo and in vitro methods for screening a compound for HDAC inhibitory activity, as well as methods for monitoring the therapeutic efficacy of an HDAC inhibitor in a subject in vivo and for determining resistance to an HDAC inhibitor in vitro or in vivo.

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/01228

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12Q1/44

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, BIOSIS, EMBASE, PAJ, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	WO 03 035843 A (BUCK INST FOR AGE RES ; BENZ CHRISTOPHER C (US)) 1 May 2003 (2003-05-01) paragraph '0015!	
T	ABRAMOVA M V ET AL: "Selective repression of c-fos gene transcription in rat embryo fibroblasts transformed by oncogenes E1A and cHa-ras." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. UNITED STATES 27 JUN 2003, vol. 306, no. 2, 27 June 2003 (2003-06-27), pages 483-487, XP002257584 ISSN: 0006-291X paragraph bridging pages 483 and 484; first paragraph of section headed "Results and discussion"	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

14 October 2003

Date of mailing of the international search report

03/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Thiele, U

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/01228

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>KUKUSHKIN ALEXANDER N ET AL: "Downregulation of c-fos gene transcription in cells transformed by E1A and cHa-ras oncogenes: a role of sustained activation of MAP/ERK kinase cascade and of inactive chromatin structure at c-fos promoter." ONCOGENE. ENGLAND 24 JAN 2002, vol. 21, no. 5, 24 January 2002 (2002-01-24), pages 719-730, XP002257585 ISSN: 0950-9232 section headed "Introduction", paragraph 1; page 720, 1. h. col., paragraph 3</p> <p>---</p>	
A	<p>DATABASE MEDLINE 'Online! US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; January 2002 (2002-01) ABRAMOVA M V ET AL: "Role of the TCF phosphorylation state and the chromatin structure in the negative transcription regulation of the c-fos proto-oncogene in E1A + c-Ha-ras transformed cells!" Database accession no. NLM11862715 XP002257586 &amp; MOLEKULIARNAIA BIOLOGIIA. RUSSIA 2002 JAN-FEB, vol. 36, no. 1, January 2002 (2002-01), pages 66-75, ISSN: 0026-8984 abstract</p> <p>---</p>	
A	<p>US 6 068 987 A (DULSKI PAULA M ET AL) 30 May 2000 (2000-05-30) claims 1,2</p> <p>-----</p>	

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 03/01228

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 4 - 6, 10 - 15, 19 - 22 and 24 are directed to methods of treatment of the human/animal body by at least surgery / methods of diagnosis carried out on the live human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No...

PCT/EP 03/01228

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03035843	A	01-05-2003	WO 03035843 A2	01-05-2003
US 6068987	A	30-05-2000	US 6110697 A	29-08-2000
			US 6428983 B1	06-08-2002